Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Delivers Q2 Sales Growth Across Its Product Lines

Executive Summary

Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.

You may also be interested in...



Boston Scientific Earns FDA Approval For Ranger Peripheral DCB

The approval of the Ranger paclitaxel-coated balloon makes Boston Scientific the only company offering both a drug-eluting stent and drug-coated balloon for treating peripheral artery disease in the US.

Boston Scientific Sees Grim Q2 But Eyes Growth By Q4 Fueled By Product Launches

The big news at Boston Scientific's first-quarter earnings call was how badly the pandemic had impacted the second quarter so far, with sales down almost $500m in April. But the company said it already saw signs that procedure volumes were beginning to bounce back.

TCT 2019: Boston Scientific's Acurate Neo TAVR Misses Endpoint In SCOPE I

Boston Scientific is looking ahead to the next-generation Acurate neo2 valve after results of SCOPE I showed worse rates of kidney injury and severe aortic regurgitation in patients treated with the self-expanding Acurate neo valve than in patients treated with Edwards’ Sapien 3 valve.

Related Content

Topics

Related Deals

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel